We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Jupiter Neurosciences is a clinical stage research and development pharmaceutical company. The Company has developed a unique resveratrol platform product targeting treatment of neuro-inflammation. The product, called JOTROL¿ , has many potential indications of use for rare diseases, which of we pri... Jupiter Neurosciences is a clinical stage research and development pharmaceutical company. The Company has developed a unique resveratrol platform product targeting treatment of neuro-inflammation. The product, called JOTROL¿ , has many potential indications of use for rare diseases, which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreichs Ataxia, and MELAS as well as ALS which is in an early development stage. In the larger disease areas, we are primarily targeting Mild Cognitive Impairment/early Alzheimers disease with TBI/concussions and Covid-19 in early development stages. Based on available scientific literature, we believe that JOTROL¿ is the first and only resveratrol product in the world that delivers a therapeutically effective dose of resveratrol in the blood stream without causing gastrointestinal side effects. Show more
Ask ADVFN Intelligence (AI)
Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a...
Jupiter, Florida, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a...
Jupiter, Florida, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a...
Jupiter, Florida, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1491 | -12.425 | 1.2 | 1.38 | 0.91 | 797763 | 1.11461198 | CS |
| 4 | -7.7591 | -88.0715096481 | 8.81 | 9.35 | 0.91 | 1221580 | 3.62243629 | CS |
| 12 | -2.9491 | -73.7275 | 4 | 19.51 | 0.91 | 772321 | 5.74084914 | CS |
| 26 | -2.9491 | -73.7275 | 4 | 19.51 | 0.91 | 772321 | 5.74084914 | CS |
| 52 | -2.9491 | -73.7275 | 4 | 19.51 | 0.91 | 772321 | 5.74084914 | CS |
| 156 | -2.9491 | -73.7275 | 4 | 19.51 | 0.91 | 772321 | 5.74084914 | CS |
| 260 | -2.9491 | -73.7275 | 4 | 19.51 | 0.91 | 772321 | 5.74084914 | CS |
tw0122
2 months ago
Invest-in-America
2 months ago
tw0122
2 months ago
Invest-in-America
2 months ago
tw0122
2 months ago
Invest-in-America
2 years ago
makinezmoney
2 years ago
Invest-in-America
2 years ago
spindog
3 years ago
crudeoil24
3 years ago
crudeoil24
3 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
